Golden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Golden State Equity Partners lifted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 2,592.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 325,684 shares of the biopharmaceutical company’s stock after buying an additional 313,587 shares during the period. Golden State Equity Partners owned about 0.16% of Sangamo Therapeutics worth $332,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of SGMO. Marshall Wace LLP raised its holdings in shares of Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 207,476 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Sangamo Therapeutics during the 2nd quarter worth $67,000. Vontobel Holding Ltd. raised its holdings in shares of Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 241,440 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares in the last quarter. Finally, Meritage Portfolio Management raised its holdings in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Down 4.9 %

NASDAQ SGMO opened at $1.17 on Tuesday. Sangamo Therapeutics, Inc. has a 12 month low of $0.30 and a 12 month high of $3.18. The business’s 50-day moving average price is $1.71 and its two-hundred day moving average price is $1.36. The firm has a market capitalization of $244.12 million, a PE ratio of -1.56 and a beta of 1.29.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. During the same quarter in the prior year, the company earned ($0.34) EPS. As a group, analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SGMO has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday, January 27th. Barclays upped their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. StockNews.com cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Truist Financial lowered their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Finally, Jefferies Financial Group lowered their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, December 31st. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.17.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.